Managing malignancy-associated hyperuricemia with rasburicase

Journal of Supportive Oncology

Volumn 3, Issue 2, 2005, Pages 117-124

  Cheson, Bruce D ^a   Dutcher, Bonni S ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLANTOIN; ALLOPURINOL; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; ELECTROLYTE; ETOPOSIDE; FLUDARABINE; HEPARIN; HYDROGEN PEROXIDE; HYPOXANTHINE; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; RASBURICASE; RECOMBINANT ENZYME; RECOMBINANT URATE OXIDASE; RITUXIMAB; SR 29142; TIOGUANINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URIC ACID; URICOZYME; VINCRISTINE; XANTHINE; XANTHINE OXIDASE;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ALKALINIZATION; ANAPHYLAXIS; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; BRONCHOSPASM; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE EXACERBATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG METABOLISM; DRUG MIXTURE; DRUG STRUCTURE; ELECTROLYTE BLOOD LEVEL; EXFOLIATIVE DERMATITIS; FEBRILE NEUTROPENIA; HEADACHE; HEMODIALYSIS; HEMOLYSIS; HIGH RISK PATIENT; HUMAN; HYDRATION; HYPERURICEMIA; HYPOXEMIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIVER TOXICITY; LYMPHATIC SYSTEM TUMOR; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; METHEMOGLOBINEMIA; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; RESPIRATORY DISTRESS; REVIEW; SEPSIS; SKIN ALLERGY; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT FAILURE; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL; VOMITING;

ALLOPURINOL; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEVER; FREE RADICAL SCAVENGERS; HUMANS; HYPERSENSITIVITY; HYPERURICEMIA; NEOPLASMS; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; URATE OXIDASE; VOMITING;

EID: 15944388558     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Davidson WB, Thakkar S, Hix JK, et al. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 2004;116:546-554.
2. Cheson BD, Frame J, Vena D, Quashu N, Sorensen JM. Tumor lysis syndrome as a rare complication of fludarabine therapy in chronic lymphocytic leukemia. J Clin Oncol 1998;16:2313-2320.
3. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004;127:3-11.
4. Annemans L, Moeremans K, Lamotte M, et al. Incidence, medical resource utilization and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukemia and non-Hodgkin's lymphoma in four European countries. Leuk Lymphoma 2003;44:77-83.
5. Holdsworth MT, Nguyen P. Role of i.v. allopurinol and rasburicase in tumor lysis syndrome. Am J Health Syst Pharm 2003;60:2213-2224.
6. Andreoli SP, Clark JH, McGuire WA, Bergstein JM. Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure. J Pediatr 1986;109:292-298.
7. Aloprim (allopurinol sulfate) [package insert]. Boca Raton, FL: Nabi Biopharmaceuticals; February, 2003.
8. Wolf G, Hegewisch-Becker S, Hossfeld DK, Stahl RA. Hyperuricemia and renal insufficiency associated with malignant disease: urate oxidase as an efficient therapy? Am J Kidney Dis 1999;34:E20.
9. Jones DP, Mahmoud H, Chesney RW.Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol 1995;9:206-212.
10. Pui CH, Mahmoud HH, Wiley JM, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001;19:697-704.
11. Mahmoud HH, Leverger G, Patte C, Harvey E, Lascombes F. Advances in the management of malignancy-associated hyperuricemia. Br J Cancer 1998;77(suppl 4):18-20.
12. Lascombes F, Sommelet D, Gebhard F, et al. High efficacy of recombinant urate oxidase in prevention of renal failure related to tumor lysis syndrome (TLS). Blood 1998;92:237B.
13. Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001;97:2998-3003.
14. Pui CH,Jeha S, Irwin D, Camitta B. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 2001;15:1505-1509.
15. Patte C, Sakiroglu C, Ansoborlo S, et al. Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia,treated in the Société Française d'Oncologie Pédiatrique LMB 89 protocol. Ann Oncol 2002;13:789-795.
16. Lee A, Li CH, So K, Chan R.Treatment of impending tumor lysis with single-dose rasburicase. Ann Pharmacother 2003;37:1614-1617.
17. Bosly A, Sonet A, Pinkerton CR, et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer 2003;98:1048-1054.
18. Arnold T, Reuter J, Delman B,Shanholtz C. Use of a single-dose of rasburicase in an obese female. Ann Pharmacother 2004;38:1428-1431.
19. Coiffier B, Mounier N, Bologna S, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphomas: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003;21:4402-4406.
20. Shipp MA, Harrington DP, Anderson JR, et al. Development of a predictive model for aggressive lymphoma: the International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-994.
21. Bell T, Candrilli S, Irish W, Morris E, Cairo MS. Medical resource use and costs associated with renal complications among patients with hematologic malignancies. In: Program/Proceedings of the 44th Annual Meeting of the American Society of Hematology; December 6-10,2002; Philadelphia, Pa. Abstract 831.